Ranibizumab biosimilar - Pfenex

Drug Profile

Ranibizumab biosimilar - Pfenex

Alternative Names: PF-582

Latest Information Update: 14 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfenex
  • Class Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Wet age-related macular degeneration
  • No development reported Diabetic macular oedema; Retinal oedema

Most Recent Events

  • 31 Aug 2016 Pfenex regained the full rights to ranibizumab biosimilar from Hospira before 30 August 2016
  • 08 Aug 2016 Pfenex will regain the full rights to ranibizumab biosimilar from Hospira
  • 08 Aug 2016 Safety, efficacy, pharmacodynamics and immunogenicity results from a phase I/II trial in age-related macular degeneration released by Pfenex .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top